Inflammatory cytokines and depression in children with cancer: A review of the literature

Abstract

Compared to the general pediatric population, pediatric cancer patients are at increased risk of experiencing depressive symptoms during and after their treatment. Clinically, there exist few resources to guide health care professionals in the care of children with cancer who report depressive symptomatology. Pediatric cancer patients experience unique inflammatory changes secondary to their disease and accompanying treatments. It has been reported that inflammatory changes in the context of illness are related to cytokine dysregulation which in turn may influence the expression of depressive symptoms. In this review of current literature, we summarize the existing knowledge, relevant models and studies in progress with respect to this concept.

Immune Microenvironment in Childhood Cancers: Characteristics and Therapeutic Challenges

“…Furthermore, the dysregulation of serum inflammatory cytokines, such as IL-1β, IL-6, and TNF-α, has been observed in pediatric patients with major depressive disorder (MDD), and it is linked to depression in children with cancer [ 97 ]. Cytokine deregulation can arise in response to cancer and its treatments, resulting in the upregulation of inflammatory reactions.…”

Depressive symptoms and oral mucositis in children with oncological diseases: a cross-sectional study

“…This condition often arises due to the side effects of cancer therapy, which include sleep disturbances, hair loss, nausea, fever, pain, and oral mucositis, among other prevalent oral manifestations. 2,3 It may also be caused by abnormal activation of the inflammatory system and its subsequent impact on the regulation of neurotransmitter production. This has been attributed to the action of cytokines such as IL-1β, IL-6, and TNF-α, observed in pediatric patients with major depressive disorder.…”

“…This has been attributed to the action of cytokines such as IL-1β, IL-6, and TNF-α, observed in pediatric patients with major depressive disorder. 3,4 Among oncology patients, depressive symptoms are a common reality, ranging from 8% to 24% across various types of cancers and Declaration of Interests: The authors certify that they have no commercial or associative interest that represents a conflict of interest in connection with the manuscript.…”

Features of immunological markers of children with oncological pathology in preoperative period

“…1). Підвищення фактора некрозу пухлини (TNF) при онкологічних захворюваннях описується багатьма авторами [6,7]. Пацієнти з раком зазнають унікальних запальних змін, вторинні по відношенню до їх захворювання та супутнього лікування.…”

“…Пацієнти з раком зазнають унікальних запальних змін, вторинні по відношенню до їх захворювання та супутнього лікування. Запальні зміни на тлі хвороби пов'язані з порушенням регуляції цитокінів, що у свою чергу може приводити до депресивних симптомів [7]. Наявність хронічного запалення підтверджується і отриманими даними, де у дітей з онкологічними захворюваннями рівень TNF та СРБ були у 2-3 рази вищими порівняно з групою порівняння.…”